<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611593</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-001-FOL1</org_study_id>
    <nct_id>NCT05611593</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety &amp; Usability of a New Formulation for Male Androgenetic Alopecia</brief_title>
  <official_title>A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Follicle Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Follicle Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration&#xD;
      of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or&#xD;
      other adverse events. It is also aimed at indicating effectiveness as compared with oral&#xD;
      Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral&#xD;
      finasteride or FOL100 location). During the study, safety and efficacy will be measured as&#xD;
      well as usability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical study aims to test the safety, tolerability and usability of FOL100&#xD;
      compared to the commercially available Finasteride 1mg Propecia in male subjects suffering&#xD;
      from AA.&#xD;
&#xD;
      Study endpoints:&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      Safety-AE(s) &amp; SAE(s) incidence rate. Secondary Endpoint: Tolerability &amp; usability collecting&#xD;
      information on safety, tolerability &amp; usability.&#xD;
&#xD;
      Exploratory Endpoint: Efficacy&#xD;
&#xD;
        1. Mean change in total, vellus and non-vellus hair count, total hair density, cumulative&#xD;
           hair diameter and mean hair thickness in the target region.&#xD;
&#xD;
        2. Global photographic assessments.&#xD;
&#xD;
        3. Subject self-assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2022</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 weeks</time_frame>
    <description>Adverse event reporting (local and general)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability &amp; Usability</measure>
    <time_frame>28 weeks</time_frame>
    <description>Subject self-assessment by questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in hair count</measure>
    <time_frame>28 weeks</time_frame>
    <description>Change in total hair count, vellus and non-vellus hair count per cm^2 as assessed by Phototrichogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total hair density</measure>
    <time_frame>28 weeks</time_frame>
    <description>Change in total hair density per cm^2 as assessed by Phototrichogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hair thickness</measure>
    <time_frame>28 weeks</time_frame>
    <description>Change in cumulative diameter and hair thickness per cm^2 as assessed by Phototrichogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Endpoint: Efficacy - self-assess</measure>
    <time_frame>28 weeks</time_frame>
    <description>Subject self-assessment by questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Androgenic Alopecia</condition>
  <arm_group>
    <arm_group_label>FOL100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will apply FOL100 lotion topically in the defined treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propecia 1mg (oral Finasteride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOL100</intervention_name>
    <description>FOL100 lotion</description>
    <arm_group_label>FOL100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propecia 1Mg Tablet</intervention_name>
    <description>Oral Finasteride</description>
    <arm_group_label>Propecia 1mg (oral Finasteride)</arm_group_label>
    <other_name>Oral Finasteride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent will be signed by the subject before starting any study&#xD;
             related procedures.&#xD;
&#xD;
          2. Male subject between the ages of 18 to 40 years old.&#xD;
&#xD;
          3. Male subject with mild to moderate vertex male-pattern hair loss, classified as grade&#xD;
             III vertex and IV, according to the modified Norwood/Hamilton Scale.&#xD;
&#xD;
          4. Subject must be willing to maintain normal shampooing habits and products during the&#xD;
             study.&#xD;
&#xD;
          5. Fitzpatrick skin phototype classification of I-IV.&#xD;
&#xD;
          6. Subjects will agree to maintain the same haircut and color throughout the study, with&#xD;
             no significant changes that will interfere with study objectives, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          7. Ability to understand and cooperate with the investigator and to comply with the&#xD;
             requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormal skin findings on the scalp, which in the opinion of&#xD;
             the investigator, could interfere with the aim of the study; in particular, abrasion,&#xD;
             actinic keratosis, inflammatory disorders, or any other abnormality.&#xD;
&#xD;
          2. Hair transplant surgery or hair weaving.&#xD;
&#xD;
          3. Clinically significant and active physical illness that could interfere with study&#xD;
             objectives or may risk patient safety as determined by the Investigator during&#xD;
             screening.&#xD;
&#xD;
          4. Ascertained or presumptive hypersensitivity to the active principle and/or any of the&#xD;
             formulation ingredients; history of anaphylaxis to drugs or allergic reactions in&#xD;
             general, which in the opinion of the investigator may affect subject safety or the&#xD;
             outcome of the study.&#xD;
&#xD;
          5. History of local infections of the skin or subcutaneous tissues of the head within 3&#xD;
             months prior to study enrollment.&#xD;
&#xD;
          6. Clinically significant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, hematological, endocrine, or neurological diseases, which in the&#xD;
             opinion of the investigator may affect subject safety or the outcome of the study.&#xD;
&#xD;
          7. Suspicion of malignancy, including prostate cancer.&#xD;
&#xD;
          8. Subject whose sexual partner(s) is pregnant or plan to become pregnant.&#xD;
&#xD;
          9. Concurrent use of systemic corticosteroids, topical corticosteroids in the area&#xD;
             treated in the study, anabolic steroids, or over the counter &quot;hair restorers&quot;.&#xD;
&#xD;
         10. Use of any of the following products in the past year that may affect hair growth:&#xD;
&#xD;
             minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic&#xD;
             interferon, psoralens, streptomycin, penicillamine ,benoxaprofen, tamoxifen,&#xD;
             phenothiazines or cytotoxic agents.&#xD;
&#xD;
         11. Use of oral finasteride or dutasteride, within 18 months prior to enrollment and 12&#xD;
             months prior to enrollment for any topical medication that is considered to affect&#xD;
             hair growth.&#xD;
&#xD;
         12. Use of a therapeutic shampoo administered by a physician with prescription within 1&#xD;
             month prior to enrollment.&#xD;
&#xD;
         13. Light or laser treatment of scalp within 3 months prior to enrollment.&#xD;
&#xD;
         14. Unwilling to undergo a superficial ink marking on the scalp vertex during V0.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solli Brawer</last_name>
    <role>Study Director</role>
    <affiliation>Follicle Pharma Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Solli Brawer</last_name>
    <phone>+972747366444</phone>
    <email>info@folliclepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Offer Fabian</last_name>
    <phone>+972747366444</phone>
    <email>info@folliclepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Martinez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lyakhovitsky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Koren</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 19, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

